Laura Kassoumeri
YOU?
Author Swipe
View article: Anti-Sp4 and anti-CCAR1 autoantibodies in UK <i>vs</i> US patients with adult and juvenile-onset anti-TIF1γ-positive myositis
Anti-Sp4 and anti-CCAR1 autoantibodies in UK <i>vs</i> US patients with adult and juvenile-onset anti-TIF1γ-positive myositis Open
Objectives Anti-transcriptional intermediary factor 1γ (TIF1γ) autoantibodies are associated with malignancy in adult-onset idiopathic inflammatory myopathy (IIM) and this risk is attenuated if patients are also positive for anti-specifici…
View article: The immune landscape of the inflamed joint defined by spectral flow cytometry
The immune landscape of the inflamed joint defined by spectral flow cytometry Open
Cellular phenotype and function are altered in different microenvironments. For targeted therapies it is important to understand site-specific cellular adaptations. Juvenile idiopathic arthritis (JIA) is characterized by autoimmune joint i…
View article: Corrigendum to “Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study” [Schizophr. Res. volume 225 (May 2023) 173–181]
Corrigendum to “Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study” [Schizophr. Res. volume 225 (May 2023) 173–181] Open
View article: TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients
TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients Open
International audience
View article: Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study
Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study Open
View article: Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration
Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration Open
Elevated brain glutamate has been implicated in non-response to antipsychotic medication in schizophrenia. Biomarkers that can accurately predict antipsychotic non-response from the first episode of psychosis (FEP) could allow stratificati…
View article: Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study
Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study Open
Objectives This prospective cohort study tested for associations between baseline cognitive performance in individuals early within their first episode and antipsychotic treatment of psychosis. We hypothesised that poorer cognitive functio…
View article: Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium
Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium Open
View article: Anterior Cingulate Glutamate Metabolites as a Predictor of Antipsychotic Response in First Episode Psychosis: data from the STRATA collaboration.
Anterior Cingulate Glutamate Metabolites as a Predictor of Antipsychotic Response in First Episode Psychosis: data from the STRATA collaboration. Open
Elevated brain glutamate has been implicated in non-response to antipsychotic medication in schizophrenia. Biomarkers that can accurately predict antipsychotic non-response from the first episode of psychosis (FEP) could allow stratificati…
View article: Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants with Treatment Resistance in Schizophrenia
Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants with Treatment Resistance in Schizophrenia Open
Importance: About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respond adequately to first-line antipsychotic treatment. This clinical presentation, chronic and highly disabling, is known as treatment-resista…
View article: Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study
Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study Open
Background 70%–84% of individuals with antipsychotic treatment resistance show non-response from the first episode. Emerging cross-sectional evidence comparing cognitive profiles in treatment resistant schizophrenia to treatment-responsive…
View article: Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA)
Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA) Open
The variability in the response to antipsychotic medication in schizophrenia may reflect between-patient differences in neurobiology. Recent cross-sectional neuroimaging studies suggest that a poorer therapeutic response is associated with…